Generated by AI
Opus Genetics, Inc. Common Stock represents an equity interest in Opus Genetics, a clinical-stage biopharmaceutical company focused on ophthalmic therapies. The company develops gene therapies for inherited retinal diseases and additional small-molecule treatments for other eye disorders, including programs aimed at retinal degeneration, refractive conditions, and other vision-related diseases. Its current pipeline includes investigational candidates such as OPGx-LCA5 and OPGx-BEST1, along with other ophthalmology-focused programs targeting specific genetic retinal conditions. Opus Genetics serves the broader vision-care market through research, development, and commercialization efforts centered on restoring or preserving sight in patients with unmet medical needs. The company is headquartered in Durham, North Carolina.
Website8 Davis Drive
Durham, NC, 27713
United States
The latest articles about IRD.
OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026 FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C.
Summary of Oct 16's posts. Generated by AI.
Summary of Sep 10's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about IRD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.